Evofem Bioscienc Stock Price, News & Analysis

Evofem Biosciences, Inc. (OTC: EVFM) is a women’s health company focused on sexual and reproductive health. According to its public disclosures and proxy materials, the company is committed to commercializing products that address unmet needs in women’s sexual and reproductive health and improving quality of life by giving people more control over their sexual and reproductive choices.

The company generates revenue from the sale of two FDA‑approved products. PHEXXI® (lactic acid, citric acid, and potassium bitartrate) is described in Evofem’s filings and news releases as the first and only hormone‑free, on‑demand prescription contraceptive vaginal gel. It is supplied in pre‑filled applicators and is applied 0–60 minutes before each act of sex. SOLOSEC® (secnidazole) 2 g oral granules is an FDA‑approved oral antimicrobial agent indicated for the treatment of two sexual health conditions: bacterial vaginosis (BV), a common vaginal infection in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection in people 12 years of age and older. Company materials state that SOLOSEC provides a complete course of therapy in a single oral dose.

Evofem’s own descriptions emphasize that PHEXXI is a locally acting, hormone‑free contraceptive that maintains vaginal pH in a range that is inhospitable to sperm and certain pathogens, and that it is intended for women who want an on‑demand, non‑hormonal option. The company highlights that PHEXXI is used before each act of intercourse and that it does not protect against sexually transmitted infections. For SOLOSEC, Evofem underscores its single‑dose regimen for BV and trichomoniasis and notes that the granules are mixed with a soft food and consumed within a short time to complete treatment.

In its definitive proxy statement and subsequent news releases, Evofem explains that it is pursuing growth both by expanding PHEXXI net product sales in the United States and by adding synergistic sexual health assets such as SOLOSEC. The company’s materials describe BV and trichomoniasis as highly prevalent conditions, and they cite external epidemiological data to illustrate the scale of these infections globally and in specific regions. Evofem also reports that BV often recurs and that adherence challenges with multi‑day regimens for other treatments can contribute to persistent infection, which is part of the rationale it presents for a single‑dose product like SOLOSEC.

Beyond the U.S. market, Evofem is building a presence in the Middle East and North Africa through licensing arrangements. Company news releases state that Pharma 1 Drug Store, an Emirati healthcare company, holds exclusive commercialization rights for PHEXXI and SOLOSEC in several Gulf Cooperation Council (GCC) states, with potential expansion to additional MENA countries. Pharma 1 is responsible for obtaining and maintaining regulatory approvals and for distribution, sales and marketing, pharmacovigilance, and other commercial functions in the licensed territory. Regulatory submissions for PHEXXI and SOLOSEC have been made in the United Arab Emirates, and Evofem has characterized these as important steps toward diversifying and expanding its revenue stream outside the United States.

Evofem also describes cost‑reduction initiatives in its proxy materials and news updates. The company reports that it is working to reduce cost of goods for both PHEXXI and SOLOSEC, including efforts to establish and validate additional manufacturing capacity for PHEXXI and to activate contract manufacturing for SOLOSEC as it transitions from selling inventory acquired from the product’s seller to selling newly manufactured goods. In its own words, the company links these initiatives to improved per‑unit profitability and to the feasibility of entering price‑sensitive global markets.

Marketing and educational campaigns are another component of Evofem’s business profile. Press releases describe activities such as the "Say Vagina" campaign, which the company characterizes as an effort to normalize clinical anatomical language, address censorship of medical terminology, and support open dialogue about vaginal health. Evofem reports that this and other social media initiatives have increased traffic to its product website for PHEXXI and raised awareness among healthcare providers and potential patients.

Corporate filings and news items also note that Evofem’s common stock trades on the over‑the‑counter market and that the company has pursued various corporate actions, including a reverse stock split authorization approved by stockholders and the termination of a previously announced merger agreement with Aditxt, Inc. These disclosures indicate that Evofem continues to operate as an independent company, with a stated focus on regaining a national listing for its stock and securing growth capital, while continuing to commercialize PHEXXI and SOLOSEC and to explore international partnerships.

Business focus and products

Based on the company’s own descriptions, Evofem’s business centers on:

• Women’s sexual and reproductive health: targeting unmet needs in contraception and treatment of common vaginal and sexually transmitted infections.
• PHEXXI contraceptive vaginal gel: a hormone‑free, on‑demand prescription product applied before intercourse.
• SOLOSEC oral granules: a single‑dose oral antimicrobial treatment for bacterial vaginosis and trichomoniasis.
• U.S. commercialization: promotion of both products to obstetricians and gynecologists and other relevant healthcare providers.
• Global expansion: licensing agreements in the Middle East and North Africa, with initial focus on the United Arab Emirates and other GCC states.

Regulatory and clinical context

Evofem’s public materials reference regulatory approvals and ongoing clinical research related to its products. PHEXXI and SOLOSEC are both FDA‑approved, and Evofem reports that SOLOSEC is the first and only single‑dose oral treatment FDA‑approved to treat both BV and trichomoniasis. The company also cites an investigator‑led, NIH‑funded Phase 4 clinical trial comparing SOLOSEC to metronidazole for trichomoniasis, as well as investigator‑led work on SOLOSEC for recurrent BV. These references are used by the company to frame its products within current treatment practices and to highlight potential advantages of single‑dose therapy.

Corporate governance and capital structure

SEC filings show that Evofem holds annual and special meetings of stockholders to vote on matters such as director elections, executive compensation on an advisory basis, equity incentive plans, reverse stock split authorization, and auditor ratification. The company has disclosed the presence of series of convertible preferred stock (Series E‑1 and Series G‑1) with voting power alongside common stock in certain proposals. An 8‑K dated October 20, 2025 describes the termination of the merger agreement with Aditxt following a stockholder vote that did not approve the transaction.

Investor information

Through its SEC filings and investor‑focused presentations, Evofem provides updates on net product sales, operating expenses, cost‑of‑goods initiatives, licensing arrangements, and capital raises via notes and warrants. An 8‑K filed on January 12, 2026 notes that the company makes a corporate slide presentation available in the investors section of its website, which is intended to summarize its business and recent developments.